anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention relates to a BCS IV drug prodrug, preparation and application thereof, in particular to a BCS IV drug prodrug containing a targeting intestinal MCT1 carrier protein, a pharmaceutical composition containing the prodrug and a preparation method thereof. The nanoparticle can obviously improve the solubility and the pharmacy of BCS IV drugs based on a &#39;solubilization-permeation promotion&#39; tandem strategy of a nanocrystallization and intestinal transporter targeting prodrug, and is used for oral administration. Belongs to the technical field of medicine. The invention provides a compound shown as a general formula (I), a geometric isomer and pharmaceutically acceptable salts, hydrates and solvates thereof: wherein X and Drug are as described in the claims and specification. The invention designs an oral prodrug taking MCT1 as a carrier based on the characteristic that an intestinal MCT1 transporter is expressed in a whole intestinal segment, so as to improve intestinal cell uptake and transport of a drug with poor membrane permeability. The pharmaceutical composition taking the high molecular material as the stabilizer has high in-vitro dissolution rate, and can further solve the problem of oral absorption of the insoluble prodrug.
PURPOSE: To obtain an anticancer agent containing the antibiotic RS-44 as an active ingredient and capable of exhibiting growth inhibiting action on various kinds of leukemia bacterial in an extremely low concentration. CONSTITUTION: This agent is obtained by including the antibiotic RS-44 as an active ingredient, mixing the active ingredient with a surfactant, a vehicle, a lubricant, a film-forming substance, etc., and preparing the mixture. The anticancer agent can be prepared in a form of capsules, tables, granules, particles, powder, suspension, injection, drops, etc., and can orally or parenterally be administered. The daily dose is about 0.01-5mg/Kg adult body in the case of oral administration and the upper limit of the daily dose is about 0.5mg/kg adult body in the case of parenteral administration. The antibiotic RS-4 is obtained by inoculating a microorganism belonging the genus Streptomyces into a culture medium and culturing the microorganism, extracting the cultured product with ethyl acetate and concentrating and purifying the extracted solution.  The antibiotic has the physical characteristics as follows: property, white powder; decomposition point, &gt;=160 deg.C; elemental analysis value: C 63.36%, H 8.69%, O 26.72%; molecular formula, C42 H70 O12 ; and molecular weight, 766 (FD mass spectrum).
The patent name: a pure natural health tea for enlarging and lifting breasts of adult females is provided. The technical field is as follows: belongs to the field of biological preparation. The problems are solved: helps solve the problem that the breasts of the adult women are too small (commonly called &#39;small chest&#39;). The technical scheme is as follows: the tea drink is prepared by the method described in the patent specification. After being taken orally, the medicine can dredge the channels and collaterals connecting the breasts, and simultaneously generate and deliver the necessary nutrients for the regrowth of the breasts, so that the regrowth of the breasts is enlarged. The main application is as follows: enlarging and lifting the chest.
PURPOSE:To use a biopsy tissue of urine, lymph cell or the like in performing easy and exact classification and identification of the bladder cancer by using a reagent contg. the antibody (marked body) separated by the hybridoma of antihuman bladder cancer antibody producing cells and the cells which can be subcultured in vitro for a long period of time. CONSTITUTION:A human bladder cancer cell strain T24 is immunized with an animal, and the antihuman cancer antibody producing cells are taken from the pulpar cells thereof. The hybridoma (syncytium) of said antibody producing cells and the cells which can be subcultured for a long period of time is obtd. from said cells and the cells of the myeloma, etc. of the animal. The resulted hybridoma is cloned and the hybridomas T-001, T-002-T-012 which secrete the antihuman cancer antibody are obtd. A marked antibody is obtd. from the antibody secreted by the same or the fraction of the antibody or enzyme and &lt;125&gt;I, etc. thereof. The marked antibody, etc. and the patient&#39;s urine and tissue slice are brought into reaction and the enzyme activity and radioactivity of the conjugate of the human bladder cancer cells and the marked antibody are measured. The easy and exact identification and classification of the bladder cancer are thus made possible with high specificity.
PURPOSE:To obtain the subject emulsified composition containing a specified amphoteric substance and a surfactant at the boundary part between the oil phase as the inner phase and the water phase as the outer phase in an oil in water type emulsified composition containing a humectant and maintaining an aqueous solution state even when the amount of the oil components is high. CONSTITUTION:This toilet water type emulsified composition is composed of oil components (&gt;=4wt.% based on the whole composition), water and a humectant and prepared by using an amphoteric substance capable of forming a get at &gt;= the ordinary temperature in an aqueous system and a surfactant in combination. In this case, the amount of the oil components is 1 to 10 times the weight of the total amount of the amphoteric substance and the surfactant and the whole amphoteric substance and surfactant exist substantially on the interface of oil drops. The viscosity of the composition is &lt;=30cps and the amphoteric substance is preferably a &gt;=16C higher alcohol or higher fatty acid. As the surfactant, a cationic surfactant or an anionic surfactant is preferably used. The oil components used in this composition contain a semisolid oil component preferably in an amount of &gt;=15wt.% based on the whole oil components. The humectant is blended preferably in an amount of &gt;=10wt.% based on the composition.
The title compounds correspond to the formula I; the symbols used are defined in Claim 1. The compounds are obtained by acylation of the optionally silylated amino group of the antibiotic derivatives of the formula II with a derivative of a carboxylic acid or thiocarboxylic acid of the formula III to form a -CE-NH linkage (E = oxygen or sulphur). Protective groups which are present are subsequently eliminated, and the  beta -lactam compounds are finally obtained as free acids or as non-toxic salts. The compounds belong to the penicillin and cephalosporin series and can accordingly be used as antibiotics and as animal feed additives. They have a broad spectrum of action while being well tolerated. &lt;IMAGE&gt;
NEW MATERIAL:A tetrapeptide derivative of formula I (R1 is H or lower alkyl; R2 is H or side chain of D-alpha-amino acid; R3 is H or lower alkyl; X is O or S) and a salt thereof. EXAMPLE:H-Tyr-(D)-Met(O)-Gly-Mephe-NHNHCONH2. USE:An analgesic agent and remedy for gastroenteric disorder, e.g. diarrhea, having an inhibitory action on gastroenteric movement and a psychotripic action expectable. Sufficent analgesic effects can be exhibited even by intravenous injection and subcutaneous administration as opposed to enkephaline, etc. PROCESS:The protecting group removed from a compound of formula II (Y1 is protecting group; Y2 is H or protecting group; R2&#39; is H or side chain of D-alpha-amino acid which may have a protecting group) to give the compound of formula I.
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to medicine. Device, moving above patient with bright white light, photographs, registers and transmits onto display screen total area of wound surface of burns, including numerical ratio in percent, with possibility of enlarging the most affected sites, for logging and monitoring dynamics of wound surface therapy. Boundaries of affection degrees are determined under intensive blue colour. Depending on affection degree specialist selects therapy for each section. Depth of skin and organ affection is also determined by device by means of ultrasonic scanner and in case of necessity depth of burn affection is displayed on monitor in two-dimensional image and snapshots for comparative dynamics of recovery are made. After determining area and degree of affection fine-aerosol of antiseptic preparation is dispersed for quick reduction of wound surface temperature and prevention of infectious complications. After application of antiseptic preparation above entire wound surface performed is phototherapy with blue spectrum with simultaneous air ventilation for reducing pain, lowing down temperature of wound surface, recovery of its microcirculation and air ablation of necrotic tissues. After required surgery medication with film-forming suspension is applied by device in form of fine aerosol, which again leads to reduction of burn surface temperature and prevents &#34;greenhouse effect&#34; of wound. After application of medication device switches on blue irradiators, spectrum of which reduces pain, restores microcirculation, activates medication and increases cell metabolism, simultaneous switching on of ultrasonic transmitter increases permeability of pores and membranes of skin and epithelium cells for medications. After the end of procedure air ventilation is switched on. ^ EFFECT: blue spectrum will make it possible to accelerate process of wound surface healing and will exclude secondary infection, ensure cytoprotective effect, activate exchange processes, improve blood supply of tissues at the level of microcirculation. ^ 5 cl, 3 dwg
The present invention relates to a combined preparation of sodium aminosalicylate and trimethoprim, which is a compound preparation made by mixing two common medicines according to a certain proportion, wherein one medicine is a conventional antituberculotic medicine and the other medicine is a traditional medicine for the new application of treating tuberculosis. The sodium aminosalicylate and the trimethoprim are used as raw materials and are mixed according to the dose proportion from 5:0.25 to 0.5. Compound sodium aminosalicylate is made by the method of producing sodium aminosalicylate tablets. Thus, the synthesis of the tubercle bacillus folic acid is blocked in two ways. The trimethoprim has stable chemical property and can be dissolved in water in a very-low amount which is greatly differed from the water solubility of the sodium aminosalicylate. Thus, the powder mix of the trimethoprim and the sodium aminosalicylate does not have chemical change. The present invention is the new antitubercular medicine which is the combined preparation providing medicine selecting chances for medical-resistant tuberculous treatment, reducing patients&#39; medication dosage and medication times, providing convenience for patients, increasing treating effects, delaying medical resistance and reducing toxic and side reaction.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an env gene of a new human endogenous retrovirus related to onset of IgA nephropathy.  &lt;P&gt;SOLUTION: An HC2env gene (env gene of the human endogenous retrovirus HC2) is disclosed. One or several bases therein may be deleted, substituted or added. The onset of the IgA nephropathy is a mechanism in which the HC2env gene is expressed to produce an HC2ENV protein that is an expression product thereof. When a human has an antibody reactive with the HC2ENV protein by an autoimmune mechanism, an immunoreactive conjugate of the antibody deposits in a glomerular mesangium region to cause chronic inflammatory reactions.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The present invention is related to a method for preparing low molecular weight hyaluronic acid from high molecular weight hyaluronic acid which is produced by  Streptococcus  sp. ID9102 (KCTC11395BP). More specifically, the invention is related to a method of reducing the molecular weight of hyaluronic acid uniformly by reacting high molecular weight hyaluronic acid with an activated carbon in certain decomposition condition while maintaining original propertied of its own. The method of the invention for lowering a molecular weight of high molecular hyaluronic acid has a convenient process without the inconvenience of reprocessing for the removal of input materials, or requiring pH treatment, various reaction catalysts, and complicated additional treatment conditions (such as heat treatment) as in a conventional method. Furthermore, the method has an effect for removing impurities. Thus, through the method, it is possible to conveniently and economically produce low molecular weight hyaluronic acid with high purity. The inventive method for lowering the molecular weight has an advantage in that according to a change of a reaction condition using activated carbon, the molecular weight of low molecular weight hyaluronic acid can be variously adjusted. The low molecular weight hyaluronic acid produced by the method of the invention can be produced in accordance with the standards of medical supplies while the hyaluronic acid&#39;s own characteristic can be maintained. Also, it can be produced in accordance with the standards of cosmetics or foods.
Dental implant system for mounting a dental superstructure is disclosed. Enossal, gingival, transgingival sections plus implant head are integrated into a single-piece implant body. The enossal and gingival sections have geometries derived from diagnostic patient data and, thus, correspond geometrically precisely to the shape of the patient&#39;s jawbone and the drilled implant cavity, completely filling those portions of the cavity. The superstructure covers the entire surface of the implant head, filling out the rest of the cavity. The surface structure of the dental implant has no gaps in it and portions of it are textured so as to facilitate complete fusing of tissue to implant, thereby preventing formation of gum pockets. Sections of the dental implant are rotationally asymmetrical, so as to ensure proper location of the implant in the cavity and prevent rotation. The construction of the implant also prevents the occurrence of micro-movements.
The present invention pertains to the field of biopharmaceutics, and particularly relates to an RNA inhibitor for inhibiting APOC3 gene expression or a pharmaceutically acceptable salt thereof. The RNA inhibitor comprises a sense strand and an antisense strand. The sense strand and the antisense strand are each independently 15-30 nucleotides, preferably 19-23 nucleotides in length. At least 80% of the bases are complementary between the sense strand and the antisense strand. The RNA inhibitor further comprises the carrier structures 5&#39;MVIP and 3&#39;MVIP. The present application further relates to a pharmaceutical composition comprising the RNA inhibitor for inhibiting APOC3 gene expression and use thereof in the treatment and prevention of cardiovascular and cerebrovascular diseases.
These novel positively charged pro-drugs of aryl anthranilic acids, represented by the general formula (1) &#39;Structure 1&#39;, have been designed and synthesized. The compounds of the general formula (1) &#39;Structure 1&#39; indicated above can be synthesized from mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin and related compounds by reaction with suitable alcohols, thiols or amines and coupling agents, such as N, N &#39;-Dicyclohexylcarbodiimide (DCC), N, N&#39; -Diisopropylcarbodiimide (DIC), O-benzotriazol-1-yl-N, N, N &#39;, N&#39; -tetramethyluronium tetrafluoroborate, O-benzotriazol-1-yl-N, N, N &#39;, N&#39; -tetramethyluronium hexafluorophosphate, benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (BOP) and the like. The positive charge on the amino group of the prodrug molecule not only can greatly improve the solubility of the drug, but also can be bonded with the negative charge on the phosphate end group of a biological membrane to push the drug to enter cytoplasm. The results of the experiments indicate that the pro-drugs permeate human skin approximately 200 times faster than the transdermal speed of mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin and related compounds. The plasma drug concentration reaches a peak value after oral administration of mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin and related compounds for about 2-4 hours, while the prodrug reaches a peak value only in about 50 minutes after transdermal administration. In plasma, more than 90% of the pro-drugs can return to the parent drug structure within a few minutes. These prodrugs can be used medicinally in treating any non-steroidal anti-inflammatory drug (NSAIAs) treatable conditions in humans or animals. These prodrugs can be administered not only orally, but also transdermally for any kind of medical treatments and therefore avoid most of the side effects of nsaids, the most prominent of which are gastrointestinal disturbances such as dyspepsia, gastroduodenal bleeding, gastric ulcerations, and gastritis. Controlled transdermal administration systems of these prodrugs enable stable maintenance of mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds at optimal therapeutic blood levels, increasing therapeutic efficacy and reducing the side effects of mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, flunixin, and related compounds. Another great benefit of transdermal delivery systems of these prodrugs is that delivery is more convenient, particularly to children.
In animals including humans, the symptoms of non-anaphylactic disease states wherein the disease victim&#39;s humoral and/or cell-mediated immunological response is involved in disease pathology are alleviated upon administration of compositions comprising mixtures of histamine and one or more immunogenic substances participative in the humoral or cell-mediated pathogenic response. In preferred embodiments, the compositions are administered in essentially minute, &#34;neutralizing&#34; doses. Illustratively, significant relief of symptoms of multiple sclerosis is achieved through parenteral (e.g., subcutaneous of sublingual) administration of mixtures of histamine and measles virus immunogen. For a majority of patients, from about 8.8×10 -6  to 5.5×10 -3  mg of histamine phosphate will provide an effective quantity of histamine to a unit dose of the mixture. Likewise, a unit dose of the mixture will contain from about 2×10 -3  to about 4×10 -4  times the prescribed vaccination dose of a killed, attenuated measles virus vaccine strain. As another example, rheumatoid arthritis symptoms are alleviated by administration of histamine admixed with an immunoglobulin G immunogen which is provocative of in vivo rheumatoid factor production. 
     Other immune disorders (e.g., chronic pain and herpes simplex type II infections) are effectively treated with admixtures of histamine and appropriate immunogen(s).
PROBLEM TO BE SOLVED: To impart the hair with natural gloss by making fine particles adsorbed to the edge portions of the hair cuticles selectively. SOLUTION: Natural gloss is imparted to the hair by making water-insoluble polymer fine particles or inorganic fine particles &gt;=0.2μm but &lt;1μm (pref. 0.3-0.9μm) in average diameter absorbed to the edge portions of the hair cuticles selectively. In this case, it is preferable that 5 or more counts of the above fine particles per 1,000μm&lt;2&gt; unit surface area of the hair are adsorbed and &gt;=70% of which is adsorbed to the edge portions. The adsorption is conducted by treating the hair with a hair cosmetic such as hair rinse, hair conditioner, hair treatment or hair spray. By virtue of the treatment, hair trimming disposition is improved with favorable touch feeling without the hair&#39;s getting sticky.
PURPOSE:To obtain the title compound useful as a preventive and remedy for diseases caused by nerve degeneration by reacting a piperidine compound with an alcohol compound in the presence of a halogenating agent, subjecting the reaction product to ring formation to give a spiro compound. and reducing the spiro compound. CONSTITUTION:A piperidine compound shown by formula I (R&lt;2&gt; is lower alkyl) is reacted with an alcohol compound shown by formula II (R&lt;1&gt; is lower alkyl; *is optically active asymmetric carbon atom) in the presence of a halogenating agent (e.g. N-bromosuccinimide) to give a compound shown by formula III (X is halogen). This compound is treated with a catalytic amount of chlorocobaloxime in the presence of sodium boron hydride to give a spiro compound shown by formula TV. Then this compound is reduced with a reducing agent such as vitride (sodium bis(2-methoxyethoxy)aluminum hydride) to give the objective compound shown by formula V.
My theory of cancer is cells that have suffered a genetic throw-back to the original life on earth.     The primitive life used carbon-dioxide as we use oxygen and emitted oxygen which was lethal to that type of life. They are cells that have suffered lack of oxygen and emit CO2 which becomes plentiful within the tumor where cancer usually start. It is possible that the tumor wall contributes to the lack of oxygen and may not allow CO2 from escaping.    The cancer cure that I have invented and proved its effectiveness is a suitable mixture of two liquids that will be refereed to as the &#34;Solution&#34;, and will be described in detail later in the Specification. It has been 100% effective 100% on skin cancers and breast cancers that are close to the outside of the breast. The use of the Solution on deep internal cancers could work well with the help of the medical profession.          The story of the years it took my invention to manifest is too long to present here.         My first experience was to cure squamous cell class one by my bottom left lip. After having proof that it worked a lady with breast cancer asked me for help. I gave her some of my Solution. She went for final test eight days later, and was found clear of cancer. A month later a registered nurse with melanoma cancer left from an operation was due for chemotherapy. She was very apprehensive of this process and asked her friend to get some Solution from me. She started to use it on a Monday evening. After using the Solution for less then four days she went for tests on Friday afternoon. She had used the Solution for less then four days. There was no cancer. One year later another lady  with breast  cancer came to me for help. I gave her some Solution and one week later the cancer was gone. Other people have had  success in curing cancer on themselves and others. They are very thankful.